Literature DB >> 19733573

Quantification of IFN-gamma produced by human purified NK cells following tumor cell stimulation: comparison of three IFN-gamma assays.

E Lion1, E L J M Smits, Z N Berneman, V F I Van Tendeloo.   

Abstract

Interferon (IFN)-gamma released by natural killer (NK) cells has become a subject of major interest, given its importance in bridging the innate and adaptive immune system. Interestingly, reports concerning tumor cell stimulation of NK cells show divergent data on which stimuli induce IFN-gamma production. Here, the question remains whether tumor cell recognition is sufficient to trigger IFN-gamma or whether a second signal is required such as type I IFN. While IFN-gamma detection methods are abundantly used with peripheral blood mononuclear cells or purified T cell fractions as responder populations, only limited data is available about comparison of these assays with purified NK cells. In this study, we assessed the relationship between stimulation of human purified resting peripheral blood NK cells with one (tumor cell or IFN-alpha) and two (tumor cell+IFN-alpha) signals by measuring IFN-gamma using three different assays. We performed the enzyme-linked immunosorbent assay (ELISA), the enzyme-linked immunospot (ELISPOT) assay and intracellular cytokine staining (ICS) assay in parallel per donor and determined whether there was a correlation between these assays. Our results show that two-signal stimulation of human resting NK cells induces significantly more IFN-gamma as compared to one-signal stimulation, readily picked up by all assays. Moreover, statistical analysis points towards a positive correlation between these assays for IFN-gamma produced following two-signal stimulation. Importantly, we show that tumor cell stimulation alone is enough to trigger secretion of IFN-gamma, but this finding was only evidenced by ELISPOT. These results reveal that the choice of IFN-gamma detection method can markedly influence the outcome regarding induction of NK cell IFN-gamma by tumor cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19733573     DOI: 10.1016/j.jim.2009.08.014

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  6 in total

Review 1.  NK cells: key to success of DC-based cancer vaccines?

Authors:  Eva Lion; Evelien L J M Smits; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-08-20

2.  Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.

Authors:  Sarah Greene; Yvette Robbins; Wojciech K Mydlarz; Angel P Huynh; Nicole C Schmitt; Jay Friedman; Lucas A Horn; Claudia Palena; Jeffrey Schlom; Dean Y Maeda; John A Zebala; Paul E Clavijo; Clint Allen
Journal:  Clin Cancer Res       Date:  2019-12-17       Impact factor: 12.531

3.  Cancer Cells Hijack PRC2 to Modify Multiple Cytokine Pathways.

Authors:  Mohamed Abou El Hassan; Katherine Huang; Manoja B K Eswara; Michael Zhao; Lan Song; Tao Yu; Yu Liu; Jeffrey C Liu; Sean McCurdy; Anqi Ma; Joan Wither; Jian Jin; Eldad Zacksenhaus; Jeffrey L Wrana; Rod Bremner
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

4.  Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner.

Authors:  Sébastien Anguille; Heleen H Van Acker; Johan Van den Bergh; Yannick Willemen; Herman Goossens; Viggo F Van Tendeloo; Evelien L Smits; Zwi N Berneman; Eva Lion
Journal:  PLoS One       Date:  2015-05-07       Impact factor: 3.240

5.  Mesoporous sodium four-coordinate aluminosilicate nanoparticles modulate dendritic cell pyroptosis and activate innate and adaptive immunity.

Authors:  Jie Tang; Yang Yang; Jingjing Qu; Wenhuang Ban; Hao Song; Zhengying Gu; Yannan Yang; Larry Cai; Shevanuja Theivendran; Yue Wang; Min Zhang; Chengzhong Yu
Journal:  Chem Sci       Date:  2022-07-20       Impact factor: 9.969

6.  Oenothein B, a cyclic dimeric ellagitannin isolated from Epilobium angustifolium, enhances IFNγ production by lymphocytes.

Authors:  Andrew G Ramstead; Igor A Schepetkin; Mark T Quinn; Mark A Jutila
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.